Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: pro...

Bibliografske podrobnosti
Main Authors:	Peng-Fei Zhang, Dan Xie, Qiu Li
Format:	Article
Jezik:	English
Izdano:	Frontiers Media S.A. 2021-02-01
Serija:	Frontiers in Public Health
Teme:	prostate cancer enzalutamide cost-effectiveness androgen deprivation therapy first-line
Online dostop:	https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full

Podobne knjige/članki

Choice of treatment options for metastatic hormone-sensitive prostate cancer
od: R. A. Gafanov, et al.
Izdano: (2020-12-01)

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
od: Onur Baser, et al.
Izdano: (2024-04-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
od: Chi-Shin Tseng, et al.
Izdano: (2023-06-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
od: B. Ya. Alekseyev, et al.
Izdano: (2019-12-01)

Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
od: Francesca Fiorentino, et al.
Izdano: (2023-04-01)

Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
od: Thomson A, et al.
Izdano: (2024-10-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
od: Kouji Izumi, et al.
Izdano: (2022-07-01)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
od: Günel Huseynova, et al.
Izdano: (2022-12-01)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
od: Alexandra Vander Ark, et al.
Izdano: (2018-05-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
od: Namrata Khurana, et al.
Izdano: (2020-01-01)

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
od: Ahmet Dirican, et al.
Izdano: (2022-11-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
od: Jukapun Yoodee, et al.
Izdano: (2022-11-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
od: T. V. Ustinova, et al.
Izdano: (2021-12-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
od: Jo-Lynn Tan, et al.
Izdano: (2017-12-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
od: Kouji Izumi, et al.
Izdano: (2017-10-01)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
od: Hui-Ming Lin, et al.
Izdano: (2021-10-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
od: Pedro Cardoso, et al.
Izdano: (2020-05-01)

Practical implications of androgen receptor inhibitors for prostate cancer treatment
od: Fabio Campodonico, et al.
Izdano: (2024-05-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
od: Sung Hee Lim, et al.
Izdano: (2024-03-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
od: Timothy C. Wright, et al.
Izdano: (2021-07-01)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
od: Anders Bjartell, et al.
Izdano: (2022-11-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
od: Zhe Zhu, et al.
Izdano: (2024-11-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
od: Marcus Moses, MS, et al.
Izdano: (2020-01-01)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
od: Pravien Rajaram, et al.
Izdano: (2020-05-01)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
od: Ralph E. White, et al.
Izdano: (2023-06-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
od: Stefanie Fischer, et al.
Izdano: (2020-01-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
od: Xiangyun You, et al.
Izdano: (2023-04-01)

MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway
od: Shengfeng Zheng, et al.
Izdano: (2024-10-01)

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer
od: Rosanne CV. Van der Roest, et al.
Izdano: (2016-07-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
od: Nair Lopes, et al.
Izdano: (2021-08-01)

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide
od: Xiaohong Xia, et al.
Izdano: (2019-05-01)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
od: Mikio Sugimoto, et al.
Izdano: (2022-09-01)

Role of Androgen Receptor-Targeted Agents in Localized Prostate Cancer
od: Jure Murgić, et al.
Izdano: (2022-01-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
od: Saizo Fujmoto, et al.
Izdano: (2023-02-01)

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
od: Zhu Wen, et al.
Izdano: (2024-08-01)

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
od: Borui Kang, et al.
Izdano: (2023-05-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
od: N. A. Avxentyev, et al.
Izdano: (2019-01-01)

Recent progress and controversies in the treatment of metastatic hormone-sensitive prostate cancer
od: Wei-hua Liu, et al.
Izdano: (2024-06-01)

New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide
od: Sergey A. Dyshlovoy, et al.
Izdano: (2023-01-01)

Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer
od: Yang Chen, et al.
Izdano: (2022-12-01)